The monoclonal antibodies developed for PD‐1 and its ligands as well as CTLA4 have been approved for the clinical therapy of several cancers (eg melanoma and non‐small‐cell lung carcinoma).33, 34. The gene discussed is PDCD1; the disease is cancer.